297 related articles for article (PubMed ID: 30773178)
1. Contact of a tumour with the pleura is not associated with regional recurrence following stereotactic ablative radiotherapy for early stage non-small cell lung cancer.
Wink KCJ; Löck S; Rossi M; van Baardwijk A; Belderbos J; de Ruysscher D; Troost EGC
Radiother Oncol; 2019 Feb; 131():120-126. PubMed ID: 30773178
[TBL] [Abstract][Full Text] [Related]
2. Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer.
Brooks ED; Sun B; Feng L; Verma V; Zhao L; Gomez DR; Liao Z; Jeter M; O'Reilly M; Welsh JW; Nguyen QN; Erasmus JJ; Eapen G; Ahrar K; Antonoff MB; Hahn SM; Heymach JV; Rice DC; Chang JY
JAMA Netw Open; 2018 Aug; 1(4):e181390. PubMed ID: 30646121
[TBL] [Abstract][Full Text] [Related]
3. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.
Senthi S; Lagerwaard FJ; Haasbeek CJ; Slotman BJ; Senan S
Lancet Oncol; 2012 Aug; 13(8):802-9. PubMed ID: 22727222
[TBL] [Abstract][Full Text] [Related]
4. The optimal treatment for patients with stage I non-small cell lung cancer: minimally invasive lobectomy versus stereotactic ablative radiotherapy - a nationwide cohort study.
de Ruiter JC; van der Noort V; van Diessen JNA; Smit EF; Damhuis RAM; Hartemink KJ;
Lung Cancer; 2024 May; 191():107792. PubMed ID: 38621343
[TBL] [Abstract][Full Text] [Related]
5. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.
Sun B; Brooks ED; Komaki RU; Liao Z; Jeter MD; McAleer MF; Allen PK; Balter PA; Welsh JD; O'Reilly MS; Gomez D; Hahn SM; Roth JA; Mehran RJ; Heymach JV; Chang JY
Cancer; 2017 Aug; 123(16):3031-3039. PubMed ID: 28346656
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer.
Lagerwaard FJ; Verstegen NE; Haasbeek CJ; Slotman BJ; Paul MA; Smit EF; Senan S
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):348-53. PubMed ID: 22104360
[TBL] [Abstract][Full Text] [Related]
7. Pleural contact decreases survival in clinical T1N0M0 lung cancer patients undergoing SBRT.
Eriguchi T; Takeda A; Tsurugai Y; Sanuki N; Kibe Y; Hara Y; Kaneko T; Taguri M; Shigematsu N
Radiother Oncol; 2019 May; 134():191-198. PubMed ID: 31005215
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic ablative radiotherapy as single treatment for early stage non-small cell lung cancer: A single institution analysis.
Zheng X; Sun Y; Ye K; Fan C; Wang X; Yang Y; Jiao R; Ge H
Thorac Cancer; 2021 Mar; 12(6):899-905. PubMed ID: 33529496
[TBL] [Abstract][Full Text] [Related]
9. Forecasting the impact of stereotactic ablative radiotherapy for early-stage lung cancer on the thoracic surgery workforce.
Edwards JP; Datta I; Hunt JD; Stefan K; Ball CG; Dixon E; Grondin SC
Eur J Cardiothorac Surg; 2016 Jun; 49(6):1599-606. PubMed ID: 26796110
[TBL] [Abstract][Full Text] [Related]
10. Impact of tumor attachment to the pleura measured by a pretreatment CT image on outcome of stage I NSCLC treated with stereotactic body radiotherapy.
Yamamoto T; Kadoya N; Shirata Y; Koto M; Sato K; Matsushita H; Sugawara T; Umezawa R; Kubozono M; Ishikawa Y; Kozumi M; Takahashi N; Ito K; Katagiri Y; Takeda K; Jingu K
Radiat Oncol; 2015 Feb; 10():35. PubMed ID: 25886315
[TBL] [Abstract][Full Text] [Related]
11. Long term outcome after 48 Gy stereotactic ablative body radiotherapy for peripheral stage I non-small cell lung cancer.
Dubaere E; Goffaux M; Wanet M; Bihin B; Gheldof C; Demoulin AS; Bolly A; Bustin F; Duplaquet F; Baugnee PE; Gustin M; Hers V; Maisin F; Marchand E; Ocak S; Pirard L; Vancutsem O; Van Neck E; Vandermoten G; Zaharia L; Remouchamps V
BMC Cancer; 2019 Jun; 19(1):639. PubMed ID: 31253136
[TBL] [Abstract][Full Text] [Related]
12. Impact of Corticosteroid Administration on Outcomes Following Stereotactic Ablative Radiotherapy for Non-small-cell Lung Cancer.
Li H; Verma V; Brooks ED; Feng L; Zhang T; Welsh JW; Lin SH; Gomez D; Gandhi S; Heymach JV; Chang JY
Clin Lung Cancer; 2019 Jul; 20(4):e480-e488. PubMed ID: 31078421
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials.
Chang JY; Senan S; Paul MA; Mehran RJ; Louie AV; Balter P; Groen HJ; McRae SE; Widder J; Feng L; van den Borne BE; Munsell MF; Hurkmans C; Berry DA; van Werkhoven E; Kresl JJ; Dingemans AM; Dawood O; Haasbeek CJ; Carpenter LS; De Jaeger K; Komaki R; Slotman BJ; Smit EF; Roth JA
Lancet Oncol; 2015 Jun; 16(6):630-7. PubMed ID: 25981812
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial.
Sun B; Brooks ED; Komaki R; Liao Z; Jeter M; McAleer M; Balter PA; Welsh JD; O'Reilly M; Gomez D; Hahn SM; Sepesi B; Rice DC; Heymach JV; Chang JY
J Thorac Oncol; 2017 Jun; 12(6):983-992. PubMed ID: 28259750
[TBL] [Abstract][Full Text] [Related]
15. Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control.
Bollineni VR; Widder J; Pruim J; Langendijk JA; Wiegman EM
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e551-5. PubMed ID: 22417800
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value and molecular correlates of a CT image-based quantitative pleural contact index in early stage NSCLC.
Lee J; Cui Y; Sun X; Li B; Wu J; Li D; Gensheimer MF; Loo BW; Diehn M; Li R
Eur Radiol; 2018 Feb; 28(2):736-746. PubMed ID: 28786009
[TBL] [Abstract][Full Text] [Related]
17. A comparison between accelerated hypofractionation and stereotactic ablative radiotherapy (SABR) for early-stage non-small cell lung cancer (NSCLC): Results of a propensity score-matched analysis.
Chiang A; Thibault I; Warner A; Rodrigues G; Palma D; Soliman H; Jain S; Poon I; Cheung P
Radiother Oncol; 2016 Mar; 118(3):478-84. PubMed ID: 26795773
[TBL] [Abstract][Full Text] [Related]
18. Impact of Lung Parenchymal-Only Failure on Overall Survival in Early-Stage Lung Cancer Patients Treated With Stereotactic Ablative Radiotherapy.
Elbanna M; Shiue K; Edwards D; Cerra-Franco A; Agrawal N; Hinton J; Mereniuk T; Huang C; Ryan JL; Smith J; Aaron VD; Burney H; Zang Y; Holmes J; Langer M; Zellars R; Lautenschlaeger T
Clin Lung Cancer; 2021 May; 22(3):e342-e359. PubMed ID: 32736936
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic Ablative Radiotherapy for stage I histologically proven non-small cell lung cancer: an Italian multicenter observational study.
Ricardi U; Frezza G; Filippi AR; Badellino S; Levis M; Navarria P; Salvi F; Marcenaro M; Trovò M; Guarneri A; Corvò R; Scorsetti M
Lung Cancer; 2014 Jun; 84(3):248-53. PubMed ID: 24681279
[TBL] [Abstract][Full Text] [Related]
20. Predicting 5-Year Progression and Survival Outcomes for Early Stage Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiation Therapy: Development and Validation of Robust Prognostic Nomograms.
Kang J; Ning MS; Feng H; Li H; Bahig H; Brooks ED; Welsh JW; Ye R; Miao H; Chang JY
Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):90-99. PubMed ID: 31586665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]